New radiation approach aims to tame pituitary tumors with fewer side effects
NCT ID NCT06826170
First seen Apr 02, 2026 · Last updated Jun 23, 2026 · Updated 13 times
Summary
This study tested a new way of delivering radiation for people with non-secreting pituitary adenomas that came back or remained after surgery. Instead of a single high dose, the radiation was given in five smaller daily doses. The goal was to see if this approach could control tumor growth while reducing damage to nearby nerves and the pituitary gland. Twenty-five patients were followed for at least a year with MRI scans, eye tests, and hormone checks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PITUITARY ADENOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fondazione IRCCS Istituto Neurologico C Besta
Milan, Milan, 20133, Italy
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
hypofractionated stereotactic radiotherapy (radiation therapy given in 5 daily sessions)
What this could lead to
If successful, this approach could offer a safer way to treat residual or recurrent pituitary tumors with fewer side effects on vision and hormone function.
What could go wrong
This is a small, early-phase study with only 25 participants. It may not confirm long-term safety or effectiveness, and some patients may still experience side effects or tumor progression.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.